Geron Corp (GERN) 3.78 $GERN Most active Nasdaq
Post# of 64074
Posted On: 03/05/2015 10:04:18 PM
Geron Corp (GERN) 3.78 $GERN
Most active Nasdaq-traded stocks
AP - Thu Mar 05, 5:04PM CST
NEW YORK (AP) — A look at Nasdaq 10 most-active stocks at the close of trading:
MU: 29.28 (+0.02), PCYC: 254.22 (+23.74), FB: 81.21 (+0.32), INTC: 33.73 (-0.39), OREX: 8.01 (-0.48), FOX: 34.03 (-0.04), GERN: 3.78 (+0.97), FOXA: 34.87 (-0.10), MSFT: 43.11 (+0.05), ZNGA: 2.41 (+0.02), AAPL: 126.41 (-2.13), CSCO: 29.30 (-0.03)
Midday Gainers / Losers
Seeking Alpha - at Seeking Alpha - Thu Mar 05, 11:45AM CST
CRMD: 7.76 (+1.60), EYES: 17.07 (+2.16), ECR: 6.57 (-0.62), CECE: 12.78 (-1.77), DRAM: 2.77 (-0.52), NVGN: 2.98 (-0.38), AMED: 28.35 (-1.08), VSLR: 11.35 (+2.82), MOMO: 11.09 (-1.46), GEF: 37.78 (-5.88), RNDY: 4.68 (+0.66), SMTC: 26.30 (-2.99), EVOK: 6.03 (+0.61), KYTH: 50.00 (+10.10), GERN: 3.78 (+0.97), LTRE: 1.73 (-0.18), ENRJ: 2.51 (+0.41), PEIX: 11.75 (+2.42), ALG: 59.19 (+9.29), CAPN: 7.37 (-1.38)
Geron gets boost from AbbVie-Pharmacyclics deal
Seeking Alpha - at Seeking Alpha - Thu Mar 05, 11:15AM CST
JNJ: 102.52 (+0.87), PCYC: 254.22 (+23.74), GERN: 3.78 (+0.97), ABBV: 56.86 (-3.41)
Geron (GERN) Flagged As Strong On High Volume
at The Street - Thu Mar 05, 9:03AM CST
Trade-Ideas LLC identified Geron (GERN) as a strong on high relative volume candidate
GERN: 3.78 (+0.97)
Key Takeaways From Geron's Earnings Release
Kanak Kanti De - at Seeking Alpha - Wed Mar 04, 2:49PM CST
GERN: 3.78 (+0.97)
Geron's Q4 Loss Narrows Y/Y, Announces Restructuring Plan - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Mar 04, 9:50AM CST
Geron Corporation (GERN) reported a fourth-quarter 2014 loss of 6 cents per share, a penny narrower than the year-ago loss of 7 cents. The Zacks Consensus Estimate was earnings of 17 cents.
JNJ: 102.52 (+0.87), GERN: 3.78 (+0.97), MRK: 57.98 (+0.10), BMY: 66.05 (+0.38)
Geron net loss improves in Q4 and FY14
Seeking Alpha - at Seeking Alpha - Wed Mar 04, 8:13AM CST
GERN: 3.78 (+0.97)
Geron Is Proof That Biotech Bargains Still Exist
Stock Doctor - Seeking Alpha - Wed Mar 04, 8:13AM CST
With the biotechnology sector hitting new highs every day and small biotech stocks sporting billion dollar valuations with minimal drug data, there are not many bargains left on the market. A little over a month ago, I recommended the small cap...
JNJ: 102.52 (+0.87), GERN: 3.78 (+0.97)
Geron's (GERN) CEO Dr. John Scarlett on Q4 2014 Results - Earnings Call Transcript
SA Transcripts - at Seeking Alpha - Tue Mar 03, 7:03PM CST
GERN: 3.78 (+0.97)
Geron reports 4Q loss
Automated Insights - Tue Mar 03, 4:54PM CST
MENLO PARK, Calif. (AP) _ Geron Corp. (GERN) on Tuesday reported a loss of $8.9 million in its fourth quarter.
GERN: 3.78 (+0.97)
Geron misses by $0.12
Seeking Alpha - at Seeking Alpha - Tue Mar 03, 3:35PM CST
GERN: 3.78 (+0.97)
Geron (GERN) Q4 2014 Results - Earnings Call Webcast
SA Transcripts - at Seeking Alpha - Tue Mar 03, 3:25PM CST
GERN: 3.78 (+0.97)
Notable earnings after Tuesday’s close
Seeking Alpha - at Seeking Alpha - Mon Mar 02, 4:35PM CST
AMBA: 64.39 (-3.10), BV: 6.26 (-0.15), AMRN: 1.67 (-0.02), AVAV: 25.80 (+0.15), BOBE: 47.76 (+1.40), TNET: 33.51 (-0.42), CECO: 6.00 (unch), VEEV: 24.73 (-0.99), REGI: 9.42 (-0.14), TIVO: 11.12 (-0.44), EGL: 34.91 (-0.56), ZLTQ: 31.76 (-0.29), LRE: 8.02 (-0.07), GERN: 3.78 (+0.97), ASNA: 13.24 (-0.14), CDXS: 3.99 (+0.09), SWHC: 14.40 (+0.06), ABM: 29.80 (+0.43)
What's in Store for Geron (GERN) this Earnings Season? - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon Mar 02, 12:00PM CST
Geron Corporation (GERN) is set to report fourth quarter 2014 results on Mar 3 after the market closes.
JNJ: 102.52 (+0.87), GERN: 3.78 (+0.97), AMRN: 1.67 (-0.02), PETX: 19.98 (+0.33)
Next Week In Biotech: Pacira PDUFA, Geron And Dendreon Report
SA Editor Mike Taylor - Seeking Alpha - Fri Feb 27, 8:00AM CST
Every Friday morning, Seeking Alpha posts a calendar of the next week's expected biotech events to start a forward-looking conversation. Please be aware that dates and events can be subject to change. Please let us know in a comment or message if you...
BRLI: 33.71 (-2.80), CASM: 1.37 (+0.03), AMRN: 1.67 (-0.02), XON: 49.50 (+1.39), OSIR: 16.94 (-0.86), CPIX: 6.75 (+0.12), AMED: 28.35 (-1.08), CTIC: 2.72 (+0.26), INSY: 57.61 (-0.46), ECYT: 6.25 (-0.48), CMRX: 40.79 (+0.05), KYTH: 50.00 (+10.10), TRIB: 18.52 (-0.08), GALE: 2.00 (+0.05), ARNA: 4.23 (-0.09), XLRN: 41.34 (+0.33), ACRX: 9.01 (-0.10), ENDP: 87.71 (+2.06), DPLO: 30.48 (-0.30), SLXP: 157.44 (+0.31), PPHM: 1.57 (+0.10), MYL: 56.69 (+1.09), CBPO: 81.80 (+2.09), RGEN: 25.78 (+0.67), HALO: 15.39 (-0.31), ALIM: 4.90 (-0.31), ACHN: 10.99 (-0.64), GERN: 3.78 (+0.97), DARA: 0.82 (-0.03), SCMP: 15.15 (+0.33), ICPT: 261.18 (-5.31), CDXS: 3.99 (+0.09), PCRX: 98.40 (+3.01), PBYI: 243.17 (+36.21), FOLD: 8.65 (+0.24)
Premarket Gainers / Losers as of 9:10 am
Seeking Alpha - at Seeking Alpha - Mon Feb 23, 8:14AM CST
VRX: 203.95 (+0.80), OIBR: 2.17 (+0.02), CLDX: 29.78 (+0.48), HSBC: 43.59 (-0.17), ASTI: 1.45 (+0.11), AXN: 1.12 (+0.32), SPPI: 6.24 (-0.06), BIOC: 3.36 (-0.03), NBG: 1.51 (+0.08), RIGL: 3.30 (+0.22), BLDP: 2.35 (+0.08), MHR: 2.65 (-0.04), CSC: 69.86 (-0.20), PPO: 59.13 (+0.01), GERN: 3.78 (+0.97), ACI: 1.12 (-0.03), TSEM: 17.81 (+0.12), HOTR: 2.07 (-0.11), DGLY: 12.38 (-0.80), HLSS: 18.45 (+0.02), XOMA: 3.65 (-0.03)
Dr. Sergei Gryaznov: Geron Should Develop Imetelstat For ET/PV
Kanak Kanti De - at Seeking Alpha - Thu Feb 19, 7:37AM CST
GERN: 3.78 (+0.97)
Seeking Alpha's Biotech Weekly: Crush-Proof Pfizer, Achillion's HCV Crusher, And More
SA Editor Mike Taylor - Seeking Alpha - Fri Feb 13, 3:00PM CST
Every Friday, Seeking Alpha's Biotech Weekly highlights the editors' picks of the week's Seeking Alpha analysis, as well as a review of the top Breaking News stories. See something here that deserves further analysis? We are always looking for new...
VRX: 203.95 (+0.80), ACT: 295.70 (-0.44), MDT: 78.50 (+0.31), XON: 49.50 (+1.39), CTIC: 2.72 (+0.26), PFNX: 14.03 (+0.43), JNJ: 102.52 (+0.87), ANTM: 146.85 (+0.30), NVAX: 8.94 (+0.11), SHPG: 238.06 (-1.58), ABBV: 56.86 (-3.41), TBPH: 20.75 (-0.76), SNY: 48.36 (+0.02), ALQA: 5.36 (+0.02), REGN: 428.95 (+15.91), ONCY: 1.05 (+0.04), PFE: 34.47 (-0.17), SLXP: 157.44 (+0.31), EPRS: 11.47 (+0.07), AMGN: 159.60 (+0.41), NKTR: 13.30 (-0.09), ZTS: 46.46 (+0.23), GILD: 103.42 (+0.36), ACHN: 10.99 (-0.64), GERN: 3.78 (+0.97)
Some Color On Geron's Presentation At The BIO Conference
Kanak Kanti De - at Seeking Alpha - Tue Feb 10, 8:15PM CST
GERN: 3.78 (+0.97)
Momentum Indicators for Biotech Equities - PDL BioPharma, Geron, Celldex Therapeutics, XOMA Corp., and Juno Therapeutics
PR Newswire - Mon Feb 09, 8:05AM CST
Investor-Edge has initiated coverage on the following equities: PDL BioPharma Inc. (NASDAQ: PDLI), Geron Corporation (NASDAQ: GERN), Celldex Therapeutics Inc. (NASDAQ: CLDX), XOMA Corporation (NASDAQ: XOMA), and Juno Therapeutics Inc. (NASDAQ: JUNO). Free research report on PDL BioPharma can be accessed at http://get.Investor-Edge.com/pdf/?c=PDL%20Bio...amp;s=PDLI. On Friday, February 06, 2015, the NASDAQ Composite ended at 4,744.40, down 0.43%, the Dow Jones Industrial Average declined 0.34%, to finish the day at 17,824.29, and the S&P 500 closed at 2,055.47, down 0.34%. The losses were broad based as eight out of ten sectors ended the session in negative. The S&P 500 Health Care Sector Index ended the day at 806.81, down 0.84%, while the index has advanced 4.07% in the last three months. Register for your complimentary reports at the links given below.
GERN: 3.78 (+0.97), CLDX: 29.78 (+0.48), JUNO: 52.03 (+2.03), XOMA: 3.65 (-0.03), PDLI: 7.10 (+0.14)
Most active Nasdaq-traded stocks
AP - Thu Mar 05, 5:04PM CST
NEW YORK (AP) — A look at Nasdaq 10 most-active stocks at the close of trading:
MU: 29.28 (+0.02), PCYC: 254.22 (+23.74), FB: 81.21 (+0.32), INTC: 33.73 (-0.39), OREX: 8.01 (-0.48), FOX: 34.03 (-0.04), GERN: 3.78 (+0.97), FOXA: 34.87 (-0.10), MSFT: 43.11 (+0.05), ZNGA: 2.41 (+0.02), AAPL: 126.41 (-2.13), CSCO: 29.30 (-0.03)
Midday Gainers / Losers
Seeking Alpha - at Seeking Alpha - Thu Mar 05, 11:45AM CST
CRMD: 7.76 (+1.60), EYES: 17.07 (+2.16), ECR: 6.57 (-0.62), CECE: 12.78 (-1.77), DRAM: 2.77 (-0.52), NVGN: 2.98 (-0.38), AMED: 28.35 (-1.08), VSLR: 11.35 (+2.82), MOMO: 11.09 (-1.46), GEF: 37.78 (-5.88), RNDY: 4.68 (+0.66), SMTC: 26.30 (-2.99), EVOK: 6.03 (+0.61), KYTH: 50.00 (+10.10), GERN: 3.78 (+0.97), LTRE: 1.73 (-0.18), ENRJ: 2.51 (+0.41), PEIX: 11.75 (+2.42), ALG: 59.19 (+9.29), CAPN: 7.37 (-1.38)
Geron gets boost from AbbVie-Pharmacyclics deal
Seeking Alpha - at Seeking Alpha - Thu Mar 05, 11:15AM CST
JNJ: 102.52 (+0.87), PCYC: 254.22 (+23.74), GERN: 3.78 (+0.97), ABBV: 56.86 (-3.41)
Geron (GERN) Flagged As Strong On High Volume
at The Street - Thu Mar 05, 9:03AM CST
Trade-Ideas LLC identified Geron (GERN) as a strong on high relative volume candidate
GERN: 3.78 (+0.97)
Key Takeaways From Geron's Earnings Release
Kanak Kanti De - at Seeking Alpha - Wed Mar 04, 2:49PM CST
GERN: 3.78 (+0.97)
Geron's Q4 Loss Narrows Y/Y, Announces Restructuring Plan - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Mar 04, 9:50AM CST
Geron Corporation (GERN) reported a fourth-quarter 2014 loss of 6 cents per share, a penny narrower than the year-ago loss of 7 cents. The Zacks Consensus Estimate was earnings of 17 cents.
JNJ: 102.52 (+0.87), GERN: 3.78 (+0.97), MRK: 57.98 (+0.10), BMY: 66.05 (+0.38)
Geron net loss improves in Q4 and FY14
Seeking Alpha - at Seeking Alpha - Wed Mar 04, 8:13AM CST
GERN: 3.78 (+0.97)
Geron Is Proof That Biotech Bargains Still Exist
Stock Doctor - Seeking Alpha - Wed Mar 04, 8:13AM CST
With the biotechnology sector hitting new highs every day and small biotech stocks sporting billion dollar valuations with minimal drug data, there are not many bargains left on the market. A little over a month ago, I recommended the small cap...
JNJ: 102.52 (+0.87), GERN: 3.78 (+0.97)
Geron's (GERN) CEO Dr. John Scarlett on Q4 2014 Results - Earnings Call Transcript
SA Transcripts - at Seeking Alpha - Tue Mar 03, 7:03PM CST
GERN: 3.78 (+0.97)
Geron reports 4Q loss
Automated Insights - Tue Mar 03, 4:54PM CST
MENLO PARK, Calif. (AP) _ Geron Corp. (GERN) on Tuesday reported a loss of $8.9 million in its fourth quarter.
GERN: 3.78 (+0.97)
Geron misses by $0.12
Seeking Alpha - at Seeking Alpha - Tue Mar 03, 3:35PM CST
GERN: 3.78 (+0.97)
Geron (GERN) Q4 2014 Results - Earnings Call Webcast
SA Transcripts - at Seeking Alpha - Tue Mar 03, 3:25PM CST
GERN: 3.78 (+0.97)
Notable earnings after Tuesday’s close
Seeking Alpha - at Seeking Alpha - Mon Mar 02, 4:35PM CST
AMBA: 64.39 (-3.10), BV: 6.26 (-0.15), AMRN: 1.67 (-0.02), AVAV: 25.80 (+0.15), BOBE: 47.76 (+1.40), TNET: 33.51 (-0.42), CECO: 6.00 (unch), VEEV: 24.73 (-0.99), REGI: 9.42 (-0.14), TIVO: 11.12 (-0.44), EGL: 34.91 (-0.56), ZLTQ: 31.76 (-0.29), LRE: 8.02 (-0.07), GERN: 3.78 (+0.97), ASNA: 13.24 (-0.14), CDXS: 3.99 (+0.09), SWHC: 14.40 (+0.06), ABM: 29.80 (+0.43)
What's in Store for Geron (GERN) this Earnings Season? - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon Mar 02, 12:00PM CST
Geron Corporation (GERN) is set to report fourth quarter 2014 results on Mar 3 after the market closes.
JNJ: 102.52 (+0.87), GERN: 3.78 (+0.97), AMRN: 1.67 (-0.02), PETX: 19.98 (+0.33)
Next Week In Biotech: Pacira PDUFA, Geron And Dendreon Report
SA Editor Mike Taylor - Seeking Alpha - Fri Feb 27, 8:00AM CST
Every Friday morning, Seeking Alpha posts a calendar of the next week's expected biotech events to start a forward-looking conversation. Please be aware that dates and events can be subject to change. Please let us know in a comment or message if you...
BRLI: 33.71 (-2.80), CASM: 1.37 (+0.03), AMRN: 1.67 (-0.02), XON: 49.50 (+1.39), OSIR: 16.94 (-0.86), CPIX: 6.75 (+0.12), AMED: 28.35 (-1.08), CTIC: 2.72 (+0.26), INSY: 57.61 (-0.46), ECYT: 6.25 (-0.48), CMRX: 40.79 (+0.05), KYTH: 50.00 (+10.10), TRIB: 18.52 (-0.08), GALE: 2.00 (+0.05), ARNA: 4.23 (-0.09), XLRN: 41.34 (+0.33), ACRX: 9.01 (-0.10), ENDP: 87.71 (+2.06), DPLO: 30.48 (-0.30), SLXP: 157.44 (+0.31), PPHM: 1.57 (+0.10), MYL: 56.69 (+1.09), CBPO: 81.80 (+2.09), RGEN: 25.78 (+0.67), HALO: 15.39 (-0.31), ALIM: 4.90 (-0.31), ACHN: 10.99 (-0.64), GERN: 3.78 (+0.97), DARA: 0.82 (-0.03), SCMP: 15.15 (+0.33), ICPT: 261.18 (-5.31), CDXS: 3.99 (+0.09), PCRX: 98.40 (+3.01), PBYI: 243.17 (+36.21), FOLD: 8.65 (+0.24)
Premarket Gainers / Losers as of 9:10 am
Seeking Alpha - at Seeking Alpha - Mon Feb 23, 8:14AM CST
VRX: 203.95 (+0.80), OIBR: 2.17 (+0.02), CLDX: 29.78 (+0.48), HSBC: 43.59 (-0.17), ASTI: 1.45 (+0.11), AXN: 1.12 (+0.32), SPPI: 6.24 (-0.06), BIOC: 3.36 (-0.03), NBG: 1.51 (+0.08), RIGL: 3.30 (+0.22), BLDP: 2.35 (+0.08), MHR: 2.65 (-0.04), CSC: 69.86 (-0.20), PPO: 59.13 (+0.01), GERN: 3.78 (+0.97), ACI: 1.12 (-0.03), TSEM: 17.81 (+0.12), HOTR: 2.07 (-0.11), DGLY: 12.38 (-0.80), HLSS: 18.45 (+0.02), XOMA: 3.65 (-0.03)
Dr. Sergei Gryaznov: Geron Should Develop Imetelstat For ET/PV
Kanak Kanti De - at Seeking Alpha - Thu Feb 19, 7:37AM CST
GERN: 3.78 (+0.97)
Seeking Alpha's Biotech Weekly: Crush-Proof Pfizer, Achillion's HCV Crusher, And More
SA Editor Mike Taylor - Seeking Alpha - Fri Feb 13, 3:00PM CST
Every Friday, Seeking Alpha's Biotech Weekly highlights the editors' picks of the week's Seeking Alpha analysis, as well as a review of the top Breaking News stories. See something here that deserves further analysis? We are always looking for new...
VRX: 203.95 (+0.80), ACT: 295.70 (-0.44), MDT: 78.50 (+0.31), XON: 49.50 (+1.39), CTIC: 2.72 (+0.26), PFNX: 14.03 (+0.43), JNJ: 102.52 (+0.87), ANTM: 146.85 (+0.30), NVAX: 8.94 (+0.11), SHPG: 238.06 (-1.58), ABBV: 56.86 (-3.41), TBPH: 20.75 (-0.76), SNY: 48.36 (+0.02), ALQA: 5.36 (+0.02), REGN: 428.95 (+15.91), ONCY: 1.05 (+0.04), PFE: 34.47 (-0.17), SLXP: 157.44 (+0.31), EPRS: 11.47 (+0.07), AMGN: 159.60 (+0.41), NKTR: 13.30 (-0.09), ZTS: 46.46 (+0.23), GILD: 103.42 (+0.36), ACHN: 10.99 (-0.64), GERN: 3.78 (+0.97)
Some Color On Geron's Presentation At The BIO Conference
Kanak Kanti De - at Seeking Alpha - Tue Feb 10, 8:15PM CST
GERN: 3.78 (+0.97)
Momentum Indicators for Biotech Equities - PDL BioPharma, Geron, Celldex Therapeutics, XOMA Corp., and Juno Therapeutics
PR Newswire - Mon Feb 09, 8:05AM CST
Investor-Edge has initiated coverage on the following equities: PDL BioPharma Inc. (NASDAQ: PDLI), Geron Corporation (NASDAQ: GERN), Celldex Therapeutics Inc. (NASDAQ: CLDX), XOMA Corporation (NASDAQ: XOMA), and Juno Therapeutics Inc. (NASDAQ: JUNO). Free research report on PDL BioPharma can be accessed at http://get.Investor-Edge.com/pdf/?c=PDL%20Bio...amp;s=PDLI. On Friday, February 06, 2015, the NASDAQ Composite ended at 4,744.40, down 0.43%, the Dow Jones Industrial Average declined 0.34%, to finish the day at 17,824.29, and the S&P 500 closed at 2,055.47, down 0.34%. The losses were broad based as eight out of ten sectors ended the session in negative. The S&P 500 Health Care Sector Index ended the day at 806.81, down 0.84%, while the index has advanced 4.07% in the last three months. Register for your complimentary reports at the links given below.
GERN: 3.78 (+0.97), CLDX: 29.78 (+0.48), JUNO: 52.03 (+2.03), XOMA: 3.65 (-0.03), PDLI: 7.10 (+0.14)
(0)
(0)Scroll down for more posts ▼